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
 	/ Activating antibodies directed at the extracellular calcium6sensing receptor 
(CaSR) have been described in autoimmune hypoparathyroidism in the setting of 
isolated hypoparathyroidism or autoimmune polyglandular syndrome type 1. 
'	
  	 A 346year6old female presented with hypocalcemia (6.0 
mg/dL) and hypomagnesemia (1.1 mg/dL) accompanied by low serum PTH (2.4 pg/mL) 
as well as urinary calcium and magnesium wasting. She was diagnosed with 
hypoparathyroidism, which was refractory to standard therapy. She was started on 60 
mg prednisone and 150 mg azathioprine treatment daily on suspicion of an autoimmune 
aetiology. The patient was tested for CaSR antibodies.  
&	 The patient was positive for CaSR antibodies of the IgG1 subtype, which 
stimulated phosphorylation of extracellular signal6regulated kinases 1 and 2 (ERK1/2) 
and inositol phosphate (IP) accumulation. Post6treatment with prednisone and 
azathioprine, her serum calcium and magnesium normalised, as did her CaSR antibody 
titre and antibody6mediated stimulation of ERK1/2 phosphorylation and IP accumulation.  
 
 This is the first demonstration of CaSR antibody6mediated 
hypoparathyroidism responsive to immunosuppressive therapy, adding to the evidence 
that autoimmune hypoparathyroidism can be, in some cases, reversible and not the 
result of autoimmune parathyroid destruction.   
1 
Page 3 of 34 Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
4 
 
"&!+. !" 2 
Blizzard and coworkers were the first to demonstrate anti6parathyroid antibodies in 3 
patients with idiopathic hypoparathyroidism, although the parathyroid antigen(s)’s 4 
identity was uncertain.1 Subsequently, the extracellular calcium6sensing receptor 5 
(CaSR) was identified as a target of anti6parathyroid antibodies.264 Later, inactivating 6 
antibodies against the receptor were demonstrated in four patients with PTH6dependent 7 
hypercalcemia, three of whom also had hypocalciuria.5 This clinical presentation is 8 
similar to that of familial hypocalciuric hypercalcemia (FHH), which is, in most cases, 9 
caused by inactivating CaSR mutations.6 CaSR antibody6mediated inhibition of CaSR 10 
activity in two of these cases was demonstrated by showing antibody6mediated 11 
inhibition of Ca2+6elicited activation of inositol phosphate (IP) accumulation and 12 
extracellular6regulated kinases 1 and 2 (ERK1/2) activity.5 13 
The same group then demonstrated activating anti6CaSR antibodies in two patients with 14 
autoimmune hypoparathyroidism.7 These patients’ clinical presentation resembled that 15 
of autosomal dominant hypoparathyroidism caused by activating CaSR mutations.6 16 
While very uncommon, additional examples of inactivating or activating CaSR 17 
antibodies have been reported in PTH6dependent hypercalcemia or hypocalcemia, 18 
respectively.8611 In one case with inactivating antibodies, the hypercalcemia was steroid 19 
responsive, while in a second it was not.8,9 20 
Here, we report a unique case of severe hypoparathyroidism caused by activating 21 
antibodies to the CaSR, which was responsive to immunosuppressive therapy. 22 
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12
	


24 
A 346year6old Caucasian female with a past medical history of hypertension, arthritis, 25 
and obesity presented to our institution with perioral and bilateral hand numbness, 26 
tingling and muscle cramps. Four months prior, she was seen at an outside hospital 27 
emergency room (ER) for abdominal pain. A CT scan of the abdomen and pelvis did not 28 
reveal any intra6abdominal pathology. A basic metabolic panel was normal, including 29 
total serum calcium of 9.0 mg/dL. She was discharged with a diagnosis of viral 30 
gastroenteritis. Eight weeks later, she presented back to the same ER with bilateral 31 
hand and perioral numbness and tingling for four days. Physical exam revealed a 32 
positive Chvostek's sign. Total serum calcium was 7.5 mg/dL (normal range, 8.3610.6 33 
mg/dL), PTH was inappropriately normal at 48 pg/mL (normal range, 14672 pg/mL), 34 
magnesium was 1.5 mg/dL (normal range, 1.862.4 mg/dL), and ionised calcium was 3.2 35 
mg/dL (normal range, 4.665.4 mg/dL). Intravenous calcium gluconate and magnesium 36 
sulphate was administered, and she was discharged on high dose calcium carbonate 37 
(1500 mg three times daily) and magnesium oxide (400 mg daily). The following day 38 
she presented to the same ER with similar symptoms. Total serum calcium was 7.5 39 
mg/dL and magnesium was 1.6 mg/dL. She received intravenous magnesium and was 40 
discharged with nephrology follow6up.41 
After nephrology evaluation, she was initiated on calcitriol (0.25 Gg twice daily) and 42 
ergocalciferol weekly; calcium carbonate and magnesium oxide were 43 
continued. Outpatient laboratory studies two days after the patient’s visit showed total 44 
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serum calcium of 6.4 mg/dL, potassium 3.5 mg/dL (normal range, 3.565.1 mg/dL), and 45 
magnesium of 1.5 mg/dL.  PTH was 30.5 pg/mL, and 256hydroxyvitamin D was 22.5 46 
ng/mL (normal, > 30 ng/mL). One week later, she presented to the ER again with47 
symptomatic hypocalcemia. She was given intravenous magnesium and calcium and 48 
discharged home. She returned to the ER the same evening with persistent 49 
symptomatic hypocalcemia. Total serum calcium was noted to be 6.3 mg/dL, ionised 50 
calcium 3.2 mg/dL, and magnesium 1.4 mg/dL. She was discharged after receiving 51 
intravenous calcium gluconate and magnesium sulphate. The following day, she 52 
presented back to the ER with worsening perioral and bilateral hands numbness and 53 
tingling as well as blurry vision and diplopia. An electrocardiogram showed prolonged 54 
QTc, and physical exam revealed positive Chvostek’s sign. She was transferred to a 55 
university hospital for persistent symptomatic hypocalcemia and hypomagnesemia.   56 
At the university hospital, additional work6up included serum cortisol level which was 57 
14.2 G/dL (normal range, 6.7622.6 G/dL).  Repeat PTH was 4.0 pg/ml and phosphate 6.3 58 
mg/dL (normal range, 2.564.5 mg/dL). Renal ultrasound showed right and left kidneys 59 
measured 12.2 cm and 10.9 cm, respectively, with normal echogenicity, no masses, 60 
calculi or nephrocalcinosis. Thyroid ultrasound showed the right and left lobes 61 
measured 4.8 cm and 5.5 cm, respectively. No discrete thyroid nodules or cysts were 62 
visualized. The parathyroid glands were not appreciated. She continued to receive 63 
intravenous calcium and magnesium and was discharged after two and a half weeks on 64 
oral amlodipine for hypertension, calcitriol, magnesium and calcium supplements, and 65 
ergocalciferol. She presented back to the same hospital within 48 h with recurrent 66 
symptomatic hypocalcemia. Total serum calcium was 6.5 mg/dL, phosphate was 5.9 67 
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mg/dL, and magnesium was 1.5 mg/dL. She received intravenous calcium and 68 
magnesium supplementation daily and was discharged after five days on calcitriol, 69 
calcium and magnesium.  70 
The following day, the patient was presented to our institution for persistent 71 
symptomatic hypocalcemia, this being her third hospitalisation. Physical examination 72 
was notable for a positive Chvostek’s sign. Total serum calcium was 6.0 mg/dL, 73 
magnesium 1.1 mg/dL, and PTH 2.4 pg/ml. Fractional excretion of calcium and 74 
magnesium were 6.45% and 23%, respectively. She was diagnosed with severe 75 
hypocalcemia and hypomagnesemia due to acquired hypoparathyroidism. She received 76 
daily intravenous calcium and magnesium to maintain serum levels close to or within 77 
the respective normal ranges. Her subsequent treatment with immunosuppressive 78 
therapy is detailed in the results section. 79 
1 &
	


80 
CaSR immunoprecipitation assays for detecting CaSR antibodies were carried out as 81 
before.12 The patient’s pre6 and post6immunosuppressive treatment serum samples (n = 82 
2), and previously studied healthy control sera (n = 10),12 were stored at 680°C. Human 83 
embryonic kidney 293 (HEK293) cells were transiently transfected with plasmid 84 
pcCaSR6FLAG. Cell extracts containing expressed CaSR6FLAG protein were prepared. 85 
Aliquots (506Nl) of GammaBind® Sepharose beads (Amersham Biosciences, Little 86 
Chalfont, UK) were mixed with sera (1:100 dilution) in duplicate in 1 ml of 87 
immunoprecipitation buffer and incubated for 1 h at 4°C. The bead/IgG complexes were 88 
collected by centrifugation and incubated with cell extract containing CaSR6FLAG 89 
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protein at 4°C for 16 h. The bead/IgG/protein complexes were collected by 90 
centrifugation, washed, denatured, and subjected to SDS6PAGE in 7.5% polyacrylamide 91 
gels. The separated proteins were transferred onto Trans6Blot® Transfer Membranes 92 
(Bio6Rad Laboratories Ltd., Hemel Hempstead, UK) using standard protocols. 93 
Immunoprecipitated CaSR6FLAG protein was detected using anti6FLAG® M2694 
Peroxidase Conjugate (Sigma6Aldrich, Poole, UK) and an ECL™ Western Blotting 95 
Analysis System (Amersham Biosciences) with a final exposure to pre6flashed x6ray film 96 
for 5 min. Densitometry was performed in a Bio6Rad GS 690 Scanning Densitometer 97 
with Multi6Analyst Version 1.1 Software (Bio6Rad Laboratories Ltd.).98 
A CaSR antibody index for each serum in the immunoprecipitation assay was calculated 99 
as the densitometry value of the test d serum/mean densitometry value of 10 control 100 
sera. The upper normal limit for the assay was calculated using the mean CaSR 101 
antibody index + 3 SD of these control individuals. A CaSR antibody index above the 102 
upper normal limit was designated as positive for CaSR antibody reactivity. All assays 103 
were run blinded to avoid operator bias.104 
1'			 &
	

	
105 
The CaSR’s response to Ca2+ was assessed in HEK293 cells stably expressing the 106 
receptor (HEK2936CaSR) by measuring intracellular inositol616phosphate (IP1) 107 
accumulation using a specific IP61 ELISA (CIS Bio International, Gif6sur6Yvette, 108 
France).11 The IP61 ELISA is highly specific, with no cross6reactivity to myo6inositol, IP2, 109 
IP3 or IP4. Results obtained using this assay are comparable to those measuring 110 
inositol phosphate by tritium6labeling.13111 
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Monolayer HEK2936CaSR cells were cultured as in 246well plates.11 The cells were 112 
washed with serum6free medium and then Ca2+6free assay buffer containing 10 mM 113 
lithium chloride.11 Cells were pre6incubated for 10 min at 37°C with duplicate IgG 114 
samples (1:100 in assay buffer) prepared from the patient’s and control sera.11 Assay 115 
buffer containing varying concentrations of calcium chloride (065 mM final concentration) 116 
was added to the cells followed by incubation for 60 min at 37°C. HEK2936CaSR cells 117 
without pre6incubation with IgG were included as experimental controls. Following 118 
incubation, cells were lysed for 30 min at 37°C with 50 Nl of 2.5% IP6One ELISA Kit 119 
Lysis Reagent (CIS Bio International, Gif6sur6Yvette, France). 120 
The accumulation of intracellular IP1 was measured (IP6One ELISA Kit, CIS Bio 121 
International), an immunoassay bas d on competition between free IP1 and IP16122 
horseradish peroxidase (HRP) conjugate for binding to anti6IP1 monoclonal antibody. 123 
IP1 accumulation is expressed as: percentage inhibition of IP16HRP binding = [1 6 IP16124 
HRP binding in stimulated cells/IP16HRP binding in unstimulated cells] x 100. Increased 125 
IP1 accumulation in the HEK2936CaSR cells produces an increase in the percentage 126 
inhibition of IP16HRP binding.  127 
13'			 &
	%&(4
128 
The CaSR’s response to Ca2+ was also assessed by measuring phosphorylation of 129 
extracellular signal6regulated kinases 1 and 2 (ERK1/2).11 HEK2936CaSR cell 130 
monolayers grown in 966well plates were incubated with IgG samples and Ca2+ exactly 131 
as above. HEK2936CaSR cells without pre6incubation with IgG were included as 132 
controls. Following incubation, cells were fixed for 20 min at room temperature with 100 133 
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Nl of 4% Cell Fixing Buffer (Cellular Activation of Signaling ELISA (CASETM) Kit, 134 
SuperArray Bioscience Corporation, Frederick, MD, USA). ERK1/2 phosphorylation was 135 
measured using the CASETM Kit (SuperArray Bioscience Corporation), and results are 136 
expressed as the ratio of phosphorylated ERK1/2 to total ERK1/2.11  137 
15 &	
	%$138 
Peptide ELISAs were used to verify the binding of CaSR antibodies to identified CaSR 139 
epitopes. Lyophilised peptides were solubilised and stored according to the 140 
manufacturer’s instructions (Cambridge Peptides Ltd., Birmingham, UK). For ELISAs, 141 
the required peptide was diluted in PBS to 200 ng/ml, and 1006Nl aliquots were used to 142 
coat the wells of a 966well microtiter plates. The plates were then incubated overnight at 143 
4°C. Excess peptide was removed by decanting, and the wells were blocked with 144 
blocking buffer (PBS containing 0.1% (w/v) Tween620 and 3% (w/v) bovine serum 145 
albumin) for 30 min at 37°C. Plates were washed four times with washing buffer (PBS 146 
containing 0.1% (v/v) Tween620).Duplicate 1006Gl samples of sera at a 1:200 dilution in 147 
blocking buffer were added to the wells. PBS was applied as a control to measure any 148 
non6specific binding of ELISA reagents in the absence of sera. The plates were 149 
incubated at room temperature for 1 h and then washed four times with washing buffer. 150 
1006Gl of goat anti6human IgG conjugated to alkaline phosphatase (Sigma6Aldrich), 151 
diluted to 1:2000 in blocking buffer, was added to each well for 1 h at room temperature. 152 
After washing five times with washing buffer, 100 Gl of alkaline phosphatase substrate 153 
Sigma Fast 6nitrophenyl phosphate (Sigma6Aldrich) were applied to each well and 154 
plates incubated at room temperature to allow color development. A LabSystems 155 
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Integrated EIA Management System spectrophotometer (Life Sciences International, 156 
Basingstoke, UK) was used to read absorption of the wells at 405 nm.157 
All sera were tested in duplicate, and the average OD405 value taken. The CaSR 158 
peptide6binding reactivity of each patient and control serum was expressed as an 159 
antibody index calculated as:  mean OD405 of tested serum/mean OD405 of a population 160 
of 16 healthy control sera. Each serum was tested in three experiments, and the mean 161 
antibody index calculated. For each ELISA, the upper limit of normal was calculated as 162 
mean antibody index + 3SD of 16 healthy individuals. Sera with an antibody index 163 
above the upper limit of normal were designated as positive for CaSR antibodies. 164 
For estimating antibody titres, sera were analysed at dilutions ranging from 1:200 to 165 
1:10,000. Titers were defined as the serum dilution at which antibody binding could still 166 
be detected above the upper limits of normal for the CaSR peptide ELISAs, as detailed 167 
above. To determine the IgG subclass of purified CaSR antibodies, anti6human IgG1, 168 
IgG2, IgG3 and IgG4 alkaline phosphatase6conjugates (Southern Biotech, Birmingham, 169 
AL, USA) were applied as the secondary antibody at a 1:2000 dilution, and antibody 170 
positivity was defined as above. 171 
167 &



172 
IgG was isolated from sera using protein G6Sepharose 4 Fast Flow (Amersham 173 
Biosciences AB, Uppsala, Sweden) affinity chromatography, according to the 174 
manufacturer’s instructions. IgG was eluted using 0.2 M glycine hydrochloride (pH 3.0), 175 
and the collected 16ml fractions neutralized with 50 Nl of 1 M Tris base (pH 9.0). 176 
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Fractions containing IgG, as determined by photometry at 280 nm, were extensively 177 
dialysed against PBS, and concentrated using an Amicon Concentrator (Amicon Inc., 178 
Beverly, MA, USA). IgG samples were sterilised with a Millex Filter Unit (Millipore Corp., 179 
Bedford, MA, USA) and stored at 10 mg/ml at –20°C. Antibodies against specific CaSR 180 
epitopes were purified using peptide affinity chromatography. The required CaSR 181 
peptides (2 mg) were coupled to CarboxyLink™ Columns according to a CarboxyLink™ 182 
Immobilization Kit (ThermoFisher Scientific, Altrincham, UK). IgG samples were applied 183 
to the peptide affinity columns in PBS, eluted in IgG Elution Buffer (ThermoFisher 184 
Scientific), and then dialysed, concentrated, and stored as detailed above. 185 


	186 
Statistical analyses were performed using Student’s unpaired  tests. values < 0.05 187 
(two6tailed) were regarded as statistically significant.188 
189 
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&	190 
1 &		  			 	
  8
	 

 191 

	
		192 
The patient had no previous personal or family history of abnormalities of calcium or 193 
magnesium metabolism, hence ruling out a genetic cause of hypoparathyroidism; 194 
therefore, an autoimmune basis was considered. Antibodies to PTH were assayed, but 195 
were not detected. The possibility that CaSR6activating antibodies were causing 196 
hypocalcemia and low PTH was investigated since such autoantibodies have been 197 
reported previously in individuals with autoimmune hypoparathyroidism.7611 While testing 198 
for antibodies was underway, she was started on immunosuppressive treatment with 199 
prednisone 60 mg and azathioprine 150 mg daily, given the severity of her clinical 200 
presentation and clinical course. In addition, she continued to receive calcitriol and oral 201 
calcium and magnesium supplements. This approach was based on the assumption 202 
that reducing the titre of such antibodies might be beneficial in this severe case of 203 
hypoparathyroidism unresponsive to aggressive therapy of calcium and magnesium 204 
supplementation. Moreover, in a previously described case of inactivating CaSR 205 
antibodies as the cause of PTH6dependent, hypocalciuric hypercalcemia, the patient’s 206 
hypercalcemia remitted during glucocorticoid therapy.8 Furthermore, given the 207 
morbidities associated with long6term steroid use, including, but not limited to, diabetes 208 
mellitus, and avascular necrosis of the hip, azathioprine was added as a steroid6sparing 209 
agent, since it was anticipated that the patient would require long6term 210 
immunosuppression based on the earlier report.8 Azathioprine is one of the oldest 211 
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immunosuppressive drugs in continuous use. It blocks the de novo pathway of purine 212 
synthesis, and its relative specificity for lymphocytes results from their lack of a salvage 213 
pathway.14 Azathioprine has been used as a steroid6sparing agent for the long6term 214 
maintenance therapy for autoimmune diseases, such as lupus nephritis and pauci6215 
immune glomerulonephritis.15616 216 
The patient’s total and ionised calcium, magnesium, and phosphate levels prior to and 217 
subsequent to treatment prednisone and azathioprine are shown in Figure 1.Forty6eight 218 
hours after starting immunosuppressive therapy, she no longer required intravenous 219 
calcium supplementation and within four days she did not require intravenous 220 
magnesium. All oral supplementation was continued. In addition, her PTH level was 2.4 221 
pg/mL and 2.0 pg/mL on hospital day 1 and day 4, respectively, while receiving 222 
calcitriol, and increased to 7.6 pg/mL after treatment with immunosuppressants. 223 
The patient was discharged home 36 days after the initial presentation at our institution 224 
on prednisone 60 mg daily and azathioprine 150 mg daily, and calcitriol 1.5 Gg daily, as 225 
well as calcium and magnesium supplements. The detailed time course of prednisone 226 
dose and serum calcium concentration after this discharge is shown in Table 1. Initially, 227 
prednisone was tapered down to 20 mg daily as an outpatient. Thirteen days later, the 228 
patient was re6hospitalised for symptomatic hypocalcemia. Total serum calcium was 6.8 229 
mg/dL, magnesium 1.3 mg/dL, phosphate 4.3 mg/dL, and PTH 2.2 pg/ml. The dose of 230 
prednisone was increased back to 60 mg and calcitrol to 2.0 Gg daily. Within three days, 231 
total serum calcium levels trended up and peaked at 13.5 mg/dL six days after the dose 232 
of prednisone was increased. She developed acute kidney injury (AKI) due to 233 
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hypercalcemia, which were resolved with intravenous fluid and withholding calcitriol and 234 
calcium supplements. She was restarted and discharged on a lower dose of calcitriol 235 
(0.5 Gg daily). 236 
Following the next taper to 40 mg prednisone, the patient relapsed again with total 237 
serum calcium at 6.9 mg/dL (Table 1). Serum calcium levels normalised when the dose 238 
of prednisone was increased back to 60 mg. Calcitrol was increased to 0.5 Gg twice 239 
daily. Again, the patient became overtly hypercalcemic and developed AKI due to 240 
concurrent increases in calcitriol and calcium supplements with the relapse. The 241 
hypercalcemia resolved after calcitriol and calcium supplements were withheld briefly. 242 
Given the severity of the patient’s hypocalcemia, her multiple ER visits and 243 
hospitalisations, and the need for daily intravenous calcium infusion to maintain serum 244 
calcium within the desired range, an attempt was not made to taper off calcitriol after 245 
immunosuppression was initiated. In our view, the benefit of continuing calcitriol was felt 246 
to outweigh any risk of ongoing treatment. Since the patient developed hypocalcemia 247 
when the prednisone dose was lowered despite the use of azathioprine as a potential 248 
steroid6spring agent, azathioprine was tapered off as it did not seem to have an effect 249 
on serum calcium levels.   250 
During the next taper in prednisone dose from 60 mg at four months after initial 251 
discharge to 0 mg at seven months after initial discharge, serum calcium concentrations 252 
remained in the range of 869 mg/dL (Table 1). In this period, the patient had recurrence 253 
of AKI so calcitrol was lowered to 0.25 Gg twice daily. Over 15 months after initial 254 
discharge, calcitrol was also tapered off gradually and the patient remains off calcitrol. 255 
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At the patient’s most recent follow6up, 1.5 years after being admitted to our institution, 256 
her serum calcium level was slightly below normal at 8.0 mg/dL and PTH was within 257 
normal at 16.1 pg/ml. Her medications now include calcium carbonate (750 mg daily), 258 
without any need for immunosuppressants or calcitrol. 259 
1+		
 &

	 260 
CaSR immunoprecipitation assays for CaSR antibodies showed that the pre6treatment 261 
serum sample from the patient tested positive: the CaSR antibody index of 18.9 for the 262 
serum sample was greater than the upper limit of normal (a CaSR antibody index of 263 
2.75) calculated from a population of 10 healthy control sera (Figure 2A). The patient’s 264 
post6treatment sample had a CaSR antibody index of 1.25, a value within the range of 265 
normal, suggesting that immunosuppressive treatment reduced CaSR antibody levels. 266 
Analysis of CaSR antibody reactivity in CaSR peptide ELISAs indicated that the 267 
recognised binding site was between amino acids 11461269 a known location for 268 
activating mutations of the CaSR (http://www.casrdb.mcgill.ca/) (Figure 2B), and that 269 
the antibody titre against this epitope was 1:2000. The CaSR antibodies against the 270 
1146126 epitope were of the IgG1 subclass (Figure 2C). 271 
1 &
			
	:7272 
To determine the effects of the CaSR antibodies on CaSR function, HEK2936CaSR 273 
cells were incubated with IgG (1:100 dilution) prior to measurement of Ca2+6induced IP1 274 
accumulation and ERK1/2 phosphorylation. The results indicated that only the patient’s 275 
pre6treatment IgG sample significantly increased the levels of IP1 accumulation (Figure 276 
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2D) and ERK1/2 phosphorylation (Figure 2E) when compared with Ca2+6stimulation of 277 
HEK2936CaSR cells that were not pre6incubated with IgG. 278 
279 
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3+

280 
CaSR antibodies occur in a substantial number of patients with idiopathic 281 
hypoparathyroidism or hypoparathyroidism as part of autoimmune polyglandular 282 
syndromes.2,7,11,12,17,18 In most cases, the biological activity of the CaSR antibodies has 283 
not been tested or was negative. Occasional patients have had biologically active caSR 284 
antibodies.7,11 Here, we describe the fifth case of autoimmune hypoparathyroidism, who 285 
harbors IgG1 CaSR antibodies activating IP accumulation and ERK1/2 and directed at 286 
an epitope known to contain naturally6occurring activating mutations 287 
(http://www.casrdb.mcgill.ca/) and to participate in receptor activation. The associated 288 
inhibition of PTH secretion   may result from activation of one or both signaling 289 
pathways or perhaps others not evaluated here. Indeed, the CaSR is known to activate 290 
multiple signaling pathways, including activation and inhibition of adenylate cyclase, 291 
stimulation of phospholipase A2, and activation of protein kinase C and various 292 
mitogen6activated protein kinases.19 Of these, activation of protein kinase C and the 293 
ERK1/2 pathway have been shown to modulate PTH secretion,20,21 although the 294 
evidence is incomplete and disparate in some cases. Nevertheless, our data show that 295 
two prominent PTH signalling pathways regulated by the CaSR are modulated by the 296 
CaSR antibodies in our patient. 297 
As in two earlier cases,7 residual parathyroid function in our case was documented 298 
despite the CaSR antibodies. In the first such report,7 the hypoparathyroidism remitted 299 
spontaneously in one case and normal appearing parathyroid tissue was documented in 300 
the second during incidental thyroid surgery.7 In the present case, the hypocalcemia 301 
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improved dramatically with immunosuppressive therapy and relapsed when the dose of 302 
prednisone was decreased. Though antibody titres were not measured during the 303 
relapse, the presumption is antibody titres were reduced with high dose steroids as 304 
hypocalcemia resolved within 48 h after dose increased similar to her prior 305 
hospitalisation. The patient had been refractory to calcitriol and high dose calcium 306 
supplements prior to prednisone initiation. The disappearance of antibodies combined 307 
with high dose calcitriol and calcium supplements during relapse caused the patient to 308 
become hypercalcemic. These cases are proof6of6principle that autoimmune 309 
hypoparathyroidism is occasionally not the result of irreversible destruction of the 310 
parathyroid glands and is at least theoretically treatable by lowering the level of 311 
circulating CaSR antibodies and/or blocking their action. In the case described here, the 312 
CaSR antibody titre decreased rapidly and markedly during immunosuppressive 313 
therapy, concomitant with restoration of normocalcemia, further supporting the 314 
pathogenic, functional role of the CaSR antibodies in this case (i.e., autoimmune 315 
hypoparathyroidism without parathyroid destruction). Indeed, at her most recent clinical 316 
follow6up, the patient was maintained normocalcemic with oral calcium supplements 317 
alone, without any need for calcitrol or immunosuppressants. This documents that her 318 
antibody6mediated hypoparathyroidism was in near total remission. 319 
An alternative therapeutic approach in patients such as ours would be to block the 320 
activating action of CaSR antibodies with a CaSR antagonist, e.g., a calcilytic.22 321 
Although there is no assurance that the drug would effectively block the action of the 322 
antibody, it, at least theoretically, could promote an inactive conformation of the 323 
receptor, thereby blocking or blunting the antibody’s action and, as a consequence, 324 
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enhancing PTH secretion and renal tubular calcium reabsorption. A brief therapeutic 325 
trial could test parathyroid secretory capacity and hence the potential therapeutic utility 326 
of this approach. 327 
It is of interest to compare the stimulatory actions of CaSR antibodies, along with their 328 
implications for the pathogenesis and treatment of the associated hypoparathyroidism, 329 
to autoimmune hypocalciuric hypercalcemia (AHH) resulting from inactivating CaSR 330 
antibodies.5,8610 Any patient having PTH6dependent hypercalcemia caused by 331 
inactivating antibodies must, by definition, have viable parathyroid tissue. This contrasts 332 
with most cases of autoimmune hypoparathyroidism associated with anti6CaSR 333 
antibodies (and/or antibodies to other parathyroid epitopes), in which there appears to 334 
be irreversible, immunologic destruction.1,17,23 It is currently unknown whether prolonged 335 
exposure to inactivating antibodies in AHH eventually damages parathyroid tissue and 336 
causes hypoparathyroidism. As noted above, hypoparathyroidism caused by activating 337 
CaSR antibodies could potentially be tested for residual parathyroid function using a 338 
calcilytic. In contrast to a CaSR antagonist in this setting, a CaSR activator is a potential 339 
therapy in AHH, by counteracting the blocking effect of the CaSR antibody, thereby 340 
restoring normocalcemia. In fact, the calcimimetic, cinacalcet, ameliorated the 341 
hypercalcemia in a case of AHH.24 It will be interesting to determine the effects of 342 
cinacalcet in additional cases of AHH. Notably, cinacalcet has also been shown to 343 
improve the hypercalcemia in several cases of FHH caused by inactivating CaSR 344 
mutations.6 345 
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In summary, this is the first demonstration of CaSR antibody6mediated 346 
hypoparathyroidism responsive to immunosuppressive therapy, adding to the evidence 347 
of the role of activating CaSR antibodies in hypoparathyroidism.  348 
349 
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	Prednisone dose and total serum calcium levels over time 

*		; 2	
		
<=

	

<4$=
0 60 9.3 
2b 20 6.8 
2.3 60 6 
2.4 60 7.4 
2.5 60 9.6 
2.6 60 10.8 
3 60 13.5 
3.1 60 12 
4 60 10.1 
6 60 8.5 
7 50 10.6 
8 40 10.5 
9 40 11 
9.2 40 9.9 
9.5c 40 6.9 
9.6 40 7 
10 60 8.6 
10.3 60 13.0 
10.5613d 60 15.268.3 
14616 60 869.2 
17618 50 8.568.8 
19620 40 8.4 
21622 30 8.6610 
23624 20 8.1 
25627 10 8.5 
28629 5 8.4 
30 0 8.6 
 
aWeek 0 is the day of discharge after the patient’s initial hospitalisation at our institution. The 
tenth place represents day of the week.  
bTime of first relapse after prednisone was tapered down to 20 mg.   
cTime of second relapse after prednisone was tapered down to 40 mg. 
dPatient re6hospitalised with recurring acute kidney injury.  
420 
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#
	$		421 
#
	  Biochemical response to immunosuppressive therapy. The patient’s serum 422 
levels of total calcium, ionised calcium, magnesium, and phosphate are shown over the 423 
course of treatment at our institution. The black arrow indicates the start of 424 
immunosuppressive therapy with prednisone (60 mg daily) and azathioprine (150 mg 425 
daily). Data are shown for total calcium (normal range, 8.3610.6 mg/dL), ionised calcium 426 
(normal range, 4.665.4 mg/dL), magnesium (normal range, 1.862.mg/dL), and phosphate 427 
(normal range, 2.564.5 mg/dL).  428 
#
	Analysis of patient CaSR antibodies.Serum samples from the patient (n = 2), 429 
and healthy controls (n = 10) were analysed for CaSR antibodies in CaSR 430 
immunoprecipitation assays at a 1:100 dilution. The patient’s serum samples were 431 
taken before and after prednisone and azathioprine treatment. The CaSR antibody 432 
index (± SD) of the pre6treatment sample is shown in panel (A) next to the CaSR 433 
antibody index value (± SD) for the patient’s post6treatment serum sample, each 434 
representing the mean of three experiments. The mean CaSR antibody index (± SD) of 435 
the group of 10 healthy control sera is shown also. The upper limit of normal for the 436 
CaSR immunoprecipitation assay was a CaSR antibody index of 2.75. Serum samples 437 
from the patient (pre6treatment) and healthy controls were tested in CaSR peptide 438 
ELISAs to determine the binding site of the patient’s CaSR antibodies. The antibody 439 
indices are in panel (B) and indicate reactivity against CaSR peptide 1146126. ELISA 440 
analysis of the IgG subclass of the patient’s CaSR antibodies is shown in (C) and 441 
indicate they were of the IgG1 subclass. Changes in IP1 accumulation and ERK1/2 442 
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phosphorylation were measured in response to Ca2+ in HEK2936CaSR cells pre6443 
incubated with the patient’s IgG samples (n = 2) at a 1:100 dilution. The IgG samples 444 
were from serum taken before and after prednisone and azathioprine treatment. IgG 445 
samples from healthy controls (n = 10) were tested. HEK2936CaSR cells without pre6446 
incubation with IgG were included. The results in panel (D) show IP1 accumulation 447 
(mean ± SD of three experiments) in Ca2+6stimulated HEK2936CaSR cells that were 448 
pre6incubated with either IgG from the patient or IgG from a single control, or that were 449 
not pre6incubated with IgG. Only the patient’s pre6treatment IgG sample significantly 450 
increased the levels of IP1 accumulation when compared with Ca2+6stimulation of 451 
HEK2936CaSR cells not pre6incubated with IgG:  values were < 0.05 when comparing 452 
Ca2+6stimulated IP1 accumulation at Ca2+ concentrations of 0.5, 1.5 and 3 mM. The 453 
results in panel (E) show ERK1/2 phosphorylation (mean ± SD of three experiments) in 454 
Ca2+6stimulated HEK2936CaSR cells pre6incubated with either IgG from the patient or 455 
IgG from a single control, or not pre6incubated with IgG. Only the patient’s pre6treatment 456 
IgG sample significantly increased the levels of ERK1/2 phosphorylation when 457 
compared with Ca2+6stimulation of HEK2936CaSR cells not pre6incubated with IgG:  458 
values were < 0.05 when comparing Ca2+6stimulated ERK1/2 phosphorylation at a 459 
stimulatory Ca2+ concentration of 1.5 mM. 460 
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